Ticker

Phio Pharmaceuticals (NASDAQ: PHIO - Get Free Report) and ProKidney (NASDAQ: PROK - Get Free Report) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their profitability, analyst recommendations, dividends, risk, earnings, valuation and institutional ownership. Insider and Institutional Ownership 57.3% of Phio Pharmaceuticals

WINSTON-SALEM, N.C., March 25, 2026 (GLOBE NEWSWIRE) -- ProKidney Corp. (Nasdaq: PROK) (“ProKidney” or the “Company"), a leading late clinical-stage cell therapy company focused on chronic kidney disease (CKD), today announced the appointment of Greg Madison as Chief Commercial Officer.

Shares of ProKidney Corp. (NASDAQ: PROK - Get Free Report) have earned a consensus rating of "Moderate Buy" from the eight ratings firms that are presently covering the firm, MarketBeat reports. Two investment analysts have rated the stock with a sell rating, one has given a hold rating, four have given a buy rating and one

ProKidney (NASDAQ: PROK - Get Free Report) will likely be releasing its Q4 2025 results before the market opens on Monday, March 16th. Analysts expect the company to announce earnings of ($0.16) per share and revenue of $0.0010 million for the quarter. Parties can find conference call details on the company's upcoming Q4 2025 earning report

PROK's main value driver is Rilparencel, which is now in a pivotal trial called PROACT 1. The FDA also accepted using eGFR slope analysis for evaluating its potential accelerated approval. PROK believes they'll be ready with their topline slope analysis by Q2 2027. So, there's a clearly outlined regulatory pathway for PROK at this point.